Irish healthcare and medicines development company Solvotrin Therapeutics has partnered with Roha APD to launch the ActiveIron brand in the German pharmacy market this June.
“This is a great opportunity for ActiveIron, we estimate that the German launch will deliver €15m in retail sales value over the next 5 years,” outlines Ronan McClafferty, Global Commercial Director for Solvotrin.
Roha ADP, a leading German healthcare company, is the largest nationwide independent pharmacy distributor in Germany. The new partnership will see ActiveIron become part of an extensive healthcare portfolio joining exceptional brands such as Beecraft, Bekunis, and Sanhelios.
“We are excited to have the opportunity to bring this fantastic product to Germany. With its novel technology and strong consumer benefits, we are confident ActiveIron will become a leading iron product in Germany,” comments Axel Hannebauer, Business Development Manager at Roha ADP. This year marks Roha’s centenary operating in the German market.
Germany is the second largest vitamin and dietary supplement market in Europe, with an estimated value of 2,500 million USD. According to McClafferty, distribution coupled with a strong training and education program will be critical to success.
“This has made the need for an established local partner paramount to our future success, working with Nicol Hoppe and the Pathfinder program at Enterprise Ireland was key to us finding a partner who shares our commitment to deliver against unmet consumer needs.”
Since its launch in late 2016, ActiveIron has become a leading brand in both the United Kingdom and Ireland and is now undertaking a global expansion program. The ground-breaking iron product was developed by Solvotrin with scientists at Trinity College Dublin. The new patent-protected technology uses a unique iron-whey protein complex to ensure iron is released in the small intestines, where it is most readily absorbed.
ActiveIron’s formulation is designed to be kind and strong. It’s clinically proven to achieve double the absorption rates of ferrous sulfate thus avoiding oxidative stress and the common side effects of oral iron.